Comparative Pharmacology
Head-to-head clinical analysis: METAXALONE versus STRIFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METAXALONE versus STRIFON FORTE DSC.
METAXALONE vs STRIFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metaxalone is a centrally acting muscle relaxant whose exact mechanism is unknown. It is thought to produce skeletal muscle relaxation by depressing the central nervous system (CNS), possibly through general CNS depression or by blocking polysynaptic reflexes in the spinal cord.
Caffeine is a central nervous system stimulant that acts as an antagonist at adenosine receptors (A1 and A2A subtypes), thereby reducing the inhibitory effects of adenosine. Dihydroergotamine is an ergot alkaloid with partial agonist activity at serotonin 5-HT1B/1D receptors, leading to vasoconstriction of cranial blood vessels. Thioridazine is a typical antipsychotic with high affinity for dopamine D2 receptors and moderate affinity for serotonin 5-HT2A, alpha1-adrenergic, and histamine H1 receptors.
800 mg orally 3 to 4 times daily
Chlorzoxazone 500 mg to 750 mg orally three to four times daily.
None Documented
None Documented
Clinical Note
moderateMetaxalone + Venlafaxine
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Venlafaxine."
Clinical Note
moderateMetaxalone + Nefazodone
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Nefazodone."
Clinical Note
moderateMetaxalone + Stiripentol
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Stiripentol."
Clinical Note
moderateMetaxalone + Clomipramine
Terminal elimination half-life is approximately 0.5 to 1.5 hours, reflecting rapid clearance and supporting short-lived clinical effects.
10-12 hours in healthy adults; prolonged to 18-24 hours in hepatic impairment or elderly
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug, with less than 1% eliminated in feces via biliary excretion.
Renal excretion of unchanged drug (70-90%) and glucuronide conjugates; biliary/fecal elimination accounts for <10%
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Clomipramine."